J. J. Kavanagh

4.1k total citations
95 papers, 3.0k citations indexed

About

J. J. Kavanagh is a scholar working on Reproductive Medicine, Oncology and Molecular Biology. According to data from OpenAlex, J. J. Kavanagh has authored 95 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Reproductive Medicine, 34 papers in Oncology and 27 papers in Molecular Biology. Recurrent topics in J. J. Kavanagh's work include Ovarian cancer diagnosis and treatment (47 papers), Endometrial and Cervical Cancer Treatments (18 papers) and Cancer Treatment and Pharmacology (12 papers). J. J. Kavanagh is often cited by papers focused on Ovarian cancer diagnosis and treatment (47 papers), Endometrial and Cervical Cancer Treatments (18 papers) and Cancer Treatment and Pharmacology (12 papers). J. J. Kavanagh collaborates with scholars based in United States, Thailand and China. J. J. Kavanagh's co-authors include Claire F. Verschraegen, Creighton L. Edwards, Andrzej P. Kudelka, Ralph S. Freedman, David M. Gershenson, A P Kudelka, Michael B. Morris, J. Taylor Wharton, C. Allen Stringer and S. M. Lippman and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Radiology.

In The Last Decade

J. J. Kavanagh

91 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. J. Kavanagh United States 32 1.2k 879 859 754 728 95 3.0k
Debra A. Bell United States 33 2.0k 1.6× 666 0.8× 668 0.8× 639 0.8× 868 1.2× 80 3.3k
Atsuhiko Sakamoto Japan 28 929 0.8× 1.0k 1.1× 618 0.7× 648 0.9× 849 1.2× 126 3.5k
Gustavo C. Rodriguez United States 29 1.2k 1.0× 733 0.8× 781 0.9× 340 0.5× 607 0.8× 78 2.7k
Paul R. Kucera United States 17 2.3k 1.9× 1.1k 1.2× 573 0.7× 1.4k 1.8× 857 1.2× 32 3.3k
Kenneth Webster United States 30 1.2k 1.0× 769 0.9× 452 0.5× 845 1.1× 709 1.0× 76 3.1k
Stefania Cosio Italy 36 1.7k 1.4× 893 1.0× 729 0.8× 757 1.0× 1.5k 2.0× 118 3.4k
Edgar Petru Austria 33 1.5k 1.2× 1.5k 1.7× 691 0.8× 749 1.0× 1.2k 1.6× 222 3.9k
Beihua Kong China 32 1.2k 1.0× 611 0.7× 1.2k 1.4× 311 0.4× 796 1.1× 121 3.1k
Deolinda Pereira Portugal 26 1.3k 1.1× 1.3k 1.5× 937 1.1× 424 0.6× 266 0.4× 86 2.8k
John P. Geisler United States 27 926 0.8× 563 0.6× 684 0.8× 411 0.5× 678 0.9× 99 2.3k

Countries citing papers authored by J. J. Kavanagh

Since Specialization
Citations

This map shows the geographic impact of J. J. Kavanagh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. J. Kavanagh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. J. Kavanagh more than expected).

Fields of papers citing papers by J. J. Kavanagh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. J. Kavanagh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. J. Kavanagh. The network helps show where J. J. Kavanagh may publish in the future.

Co-authorship network of co-authors of J. J. Kavanagh

This figure shows the co-authorship network connecting the top 25 collaborators of J. J. Kavanagh. A scholar is included among the top collaborators of J. J. Kavanagh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. J. Kavanagh. J. J. Kavanagh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kavanagh, J. J., Michael W. Sill, Pedro T. Ramírez, et al.. (2007). Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. International Journal of Gynecological Cancer. 18(3). 460–464. 10 indexed citations
2.
Fu, Siqing, J. J. Kavanagh, Wei Hu, & Robert C. Bast. (2006). Clinical application of oxaliplatin in epithelial ovarian cancer. International Journal of Gynecological Cancer. 16(5). 1717–1732. 23 indexed citations
3.
Fu, Siqing, J. J. Kavanagh, Wei Hu, & Robert C. Bast. (2006). Clinical application of oxaliplatin in epithelial ovarian cancer. International Journal of Gynecological Cancer. 16(5). 1717–1732. 2 indexed citations
4.
5.
Montero, Alberto J., C. Marcela Díaz‐Montero, Anaís Malpica, Pedro T. Ramírez, & J. J. Kavanagh. (2003). Langerhans cell histiocytosis of the female genital tract: A literature review. International Journal of Gynecological Cancer. 13(3). 381–388.
6.
Montero, Alberto J., C. Marcela Díaz‐Montero, Anaís Malpica, Pedro T. Ramírez, & J. J. Kavanagh. (2003). Langerhans cell histiocytosis of the female genital tract: A literature review. International Journal of Gynecological Cancer. 13(3). 381–388. 14 indexed citations
7.
Hu, Wei, Claire F. Verschraegen, Weixin Wu, et al.. (2002). Activity of ALRT 1550, a new retinoid, with interferon-gamma on ovarian cancer cell lines. International Journal of Gynecological Cancer. 12(2). 202–207. 6 indexed citations
8.
Verschraegen, Claire F., Charles Levenback, Judith K. Wolf, et al.. (2000). Phase II Study of Intravenous DX‐8951f in Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer Refractory to Platinum, Taxane, and Topotecan. Annals of the New York Academy of Sciences. 922(1). 349–351. 3 indexed citations
9.
Fisk, Bryan, et al.. (1997). Existent proliferative responses of peripheral blood mononuclear cells from healthy donors and ovarian cancer patients to HER-2 peptides.. PubMed. 17(1A). 45–53. 37 indexed citations
10.
Kaye, S.B., Martine Piccart, Matti Aapro, Prudence A. Francis, & J. J. Kavanagh. (1997). Phase II trials of docetaxel (taxotere®) in advanced ovarian cancer—an updated overview. European Journal of Cancer. 33(13). 2167–2170. 95 indexed citations
11.
Kudelka, Andrzej P., et al.. (1996). Combination therapy with leuprolide acetate and tamoxifen in refractory ovarian cancer. International Journal of Gynecological Cancer. 6(1). 15–19. 7 indexed citations
12.
Lippman, S. M., et al.. (1995). Phase II study of cisplatin, 5-fluorouracil and interferon-α in recurrent carcinoma of the cervix. Investigational New Drugs. 13(1). 73–76. 5 indexed citations
13.
Tresukosol, Damrong, et al.. (1995). Recurrent ovarian granulosa cell tumor: a case report of a dramatic response to Taxol. International Journal of Gynecological Cancer. 5(2). 156–159. 24 indexed citations
14.
Kim, E. Edmund, et al.. (1995). Recurrent ovarian endodermal sinus tumor: demonstration by computed tomography, magnetic resonance imaging, and positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging. 22(10). 1214–1217. 1 indexed citations
15.
Kavanagh, J. J., Creighton L. Edwards, Ralph S. Freedman, et al.. (1995). A Trial of Lobaplatin (D-19466) in Platinum-Resistant Ovarian Cancer. Gynecologic Oncology. 58(1). 106–109. 24 indexed citations
16.
Vadhan‐Raj, Saroj, et al.. (1994). Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer.. Journal of Clinical Oncology. 12(4). 707–714. 31 indexed citations
17.
Lippman, S. M., J. J. Kavanagh, M. Paredes-Espinoza, et al.. (1993). 13-cis-Retinoic Acid Plus Interferon- 2a in Locally Advanced Squamous Cell Carcinoma of the Cervix. JNCI Journal of the National Cancer Institute. 85(6). 499–500. 76 indexed citations
18.
Finan, Michael A., William S. Roberts, & J. J. Kavanagh. (1993). Ovarian Sertoli-Leydig cell tumor: success with salvage therapy. International Journal of Gynecological Cancer. 3(3). 189–191. 4 indexed citations
19.
Rosenblum, M. G., J. J. Kavanagh, Thomas W. Burke, et al.. (1991). Clinical Pharmacology, Metabolism, and Tissue Distribution of 90Y-Labeled Monoclonal Antibody B72.3 After Intraperitoneal Administration. JNCI Journal of the National Cancer Institute. 83(22). 1629–1636. 30 indexed citations
20.
Blanchard, D. Kay, et al.. (1988). Infiltration of interleukin-2-inducible killer cells in ascitic fluid and pleural effusions of advanced cancer patients.. PubMed. 48(22). 6321–7. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Debra A. Bell Breakdown of academic impact, for papers by Atsuhiko Sakamoto Breakdown of academic impact, for papers by Gustavo C. Rodriguez Breakdown of academic impact, for papers by Paul R. Kucera Breakdown of academic impact, for papers by Kenneth Webster Breakdown of academic impact, for papers by Stefania Cosio Breakdown of academic impact, for papers by Edgar Petru Breakdown of academic impact, for papers by Beihua Kong Breakdown of academic impact, for papers by Deolinda Pereira Breakdown of academic impact, for papers by John P. Geisler
Rankless by CCL
2026